The PPARα ligand fenofibrate: meeting multiple targets in diabetic nephropathy

Fibrate peroxisome proliferator-activated receptor (PPAR)-α ligands are mainly used as hypolipidemic drugs. But this commentary highlights their potential in treating insulin resistance, dyslipidemia, and hypertension and in preventing diabetic nephropathy, inflammation, and cardiovascular disease. Because diabetes is a major contributor to chronic kidney disease and cardiovascular disease, PPAR-α agonists may provide greater opportunities for hitting multiple targets in this complex metabolic disease